As William Lyon Homes (WLH) Share Value Declined, Second Curve Capital Has Raised by $1.49 Million Its Stake; Bvf Has Lowered Its Chemocentryx (CCXI) Position by $5.02 Million; Valuation Rose




August 30, 2018 – By Jimmy Cauthen

William Lyon Homes (NYSE:WLH) Logo

Bvf Inc decreased its stake in Chemocentryx Inc (CCXI) by 5.09% based on its latest 2018Q1 regulatory filing with the SEC. Bvf Inc sold 386,100 shares as the company’s stock rose 32.26% while stock markets declined. The hedge fund held 7.20M shares of the health care company at the end of 2018Q1, valued at $97.94M, down from 7.59 million at the end of the previous reported quarter. Bvf Inc who had been investing in Chemocentryx Inc for a number of months, seems to be less bullish one the $649.13 million market cap company. The stock increased 0.98% or $0.125 during the last trading session, reaching $12.885. About 41,878 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 83.50% since August 30, 2017 and is uptrending. It has outperformed by 70.93% the S&P500. Some Historical CCXI News: 09/05/2018 – CHEMOCENTRYX INC – EXPECTS TO UTILIZE CASH AND INVESTMENTS BETWEEN $65 MLN AND $75 MLN FOR TWELVE MONTHS ENDING DECEMBER 31, 2018; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in; 13/03/2018 – CHEMOCENTRYX INC CCXI.O : JP MORGAN RAISES TARGET PRICE TO $16 FROM $13; 31/03/2018 – ChemoCentryx Conference Set By H.C. Wainwright for Apr. 8-10; 10/05/2018 – Invus Public Equities Advisors Exits Position in ChemoCentryx; 11/04/2018 – ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting; 09/03/2018 ChemoCentryx 4Q EPS 80c; 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 09/03/2018 – ChemoCentryx 4Q Rev $56.3M; 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En

Second Curve Capital Llc increased its stake in William Lyon Homes (WLH) by 8.46% based on its latest 2018Q1 regulatory filing with the SEC. Second Curve Capital Llc bought 55,000 shares as the company’s stock declined 7.70% with the market. The hedge fund held 705,500 shares of the homebuilding company at the end of 2018Q1, valued at $19.39M, up from 650,500 at the end of the previous reported quarter. Second Curve Capital Llc who had been investing in William Lyon Homes for a number of months, seems to be bullish on the $748.81M market cap company. The stock decreased 0.47% or $0.0925 during the last trading session, reaching $19.7175. About 113,175 shares traded. William Lyon Homes (NYSE:WLH) has risen 6.93% since August 30, 2017 and is uptrending. It has underperformed by 5.64% the S&P500. Some Historical WLH News: 25/05/2018 – WILLIAM LYON HOMES – CO, UNIT ENTERED INTO A NEW CREDIT AGREEMENT PROVIDING FOR UNSECURED REVOLVING CREDIT FACILITY OF UP TO $325.0 MLN – SEC FILING; 08/05/2018 – William Lyon Homes 1Q Net $8.33M; 09/03/2018 – William Lyon Homes Completes Acquisition Of RSI Communities, A Southern California And Texas Based Homebuilder; 08/05/2018 – William Lyon Homes 1Q Adj EPS 27c; 08/05/2018 – WILLIAM LYON HOMES – DOLLAR VALUE OF HOMES IN BACKLOG WAS $752.1 MLN AS OF MARCH 31, 2018; 08/05/2018 – WILLIAM LYON HOMES – QTRLY HOME SALES REVENUE OF $372.4 MLN, UP 44%; 25/05/2018 – WILLIAM LYON HOMES – NEW FACILITY REPLACES CO’S PREVIOUS $170 MLN REVOLVING CREDIT FACILITY; 06/03/2018 – WILLIAM LYON HOMES – TO USE PROCEEDS FROM OFFERING, $200.0 MLN CASH FROM CERTAIN LAND BANKING ARRANGEMENTS, CASH, TO FINANCE RSI ACQUISITION; 29/03/2018 – William Lyon Closes Above 50-Day Moving Average: Technicals; 08/05/2018 – William Lyon Homes 1Q EPS 21c

Among 5 analysts covering William Lyon Homes (NYSE:WLH), 1 have Buy rating, 0 Sell and 4 Hold. Therefore 20% are positive. William Lyon Homes had 18 analyst reports since August 29, 2015 according to SRatingsIntel. The stock of William Lyon Homes (NYSE:WLH) earned “Outperform” rating by Wedbush on Tuesday, July 10. The company was initiated on Tuesday, June 19 by Citigroup. Citigroup downgraded the stock to “Hold” rating in Thursday, January 4 report. The company was downgraded on Thursday, January 12 by JMP Securities. Zacks upgraded the shares of WLH in report on Saturday, August 29 to “Sell” rating. The firm has “Hold” rating given on Thursday, September 17 by Zacks. The company was maintained on Wednesday, November 1 by UBS. The company was initiated on Tuesday, December 6 by Wedbush. Zacks upgraded William Lyon Homes (NYSE:WLH) on Friday, September 4 to “Hold” rating. The stock of William Lyon Homes (NYSE:WLH) has “Neutral” rating given on Thursday, August 2 by Citigroup.

Second Curve Capital Llc, which manages about $545.33M and $259.77M US Long portfolio, decreased its stake in Zions Bancorporation (NASDAQ:ZIONW) by 235,300 shares to 258,052 shares, valued at $5.24 million in 2018Q1, according to the filing. It also reduced its holding in Meta Finl Group Inc (NASDAQ:CASH) by 55,000 shares in the quarter, leaving it with 293,132 shares, and cut its stake in Tristate Capital Holdings Inc (NASDAQ:TSC).

Bvf Inc, which manages about $999.89 million and $986.48M US Long portfolio, upped its stake in Forward Pharma A/S by 1.30M shares to 4.76M shares, valued at $10.32M in 2018Q1, according to the filing. It also increased its holding in Immune Design Corp (NASDAQ:IMDZ) by 2.64 million shares in the quarter, for a total of 4.11M shares, and has risen its stake in Pieris Pharmaceuticals Inc.

Among 7 analysts covering ChemoCentryx (NASDAQ:CCXI), 4 have Buy rating, 1 Sell and 2 Hold. Therefore 57% are positive. ChemoCentryx had 10 analyst reports since September 3, 2015 according to SRatingsIntel. The rating was downgraded by JP Morgan to “Neutral” on Tuesday, August 14. The firm earned “Overweight” rating on Tuesday, March 13 by JP Morgan. As per Tuesday, August 8, the company rating was maintained by Cowen & Co. The stock has “Sell” rating by Zacks on Monday, September 21. The firm has “Mkt Outperform” rating by JMP Securities given on Tuesday, February 21. The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) earned “Buy” rating by JMP Securities on Thursday, August 10. The firm has “Sell” rating by Zacks given on Thursday, September 3.

Analysts await ChemoCentryx, Inc. (NASDAQ:CCXI) to report earnings on November, 6. They expect $-0.25 EPS, down 92.31% or $0.12 from last year’s $-0.13 per share. After $-0.14 actual EPS reported by ChemoCentryx, Inc. for the previous quarter, Wall Street now forecasts 78.57% negative EPS growth.

Investors sentiment decreased to 1 in Q1 2018. Its down 0.30, from 1.3 in 2017Q4. It fall, as 10 investors sold CCXI shares while 36 reduced holdings. 24 funds opened positions while 22 raised stakes. 24.22 million shares or 3.03% more from 23.51 million shares in 2017Q4 were reported. Bank & Trust Of Montreal Can owns 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 10,828 shares. Northern Tru reported 276,280 shares. New York-based Financial Bank Of Mellon has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Alliancebernstein Ltd Partnership accumulated 40,100 shares or 0% of the stock. Missouri-based American Century has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). J Goldman And Ltd Partnership holds 39,000 shares. Ellington Mgmt Group Llc owns 25,200 shares. 637 are held by Meeder Asset. Invesco Limited stated it has 49,265 shares. Bridgeway holds 0.01% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 50,246 shares. Thompson Davis And Com holds 625 shares. Jpmorgan Chase And accumulated 67,861 shares. 15,708 are held by Jacobs Levy Equity Mgmt. Bnp Paribas Arbitrage has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). 38,188 were reported by California State Teachers Retirement Systems.

More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Globenewswire.com which released: “ChemoCentryx Reports Second Quarter 2018 Financial Results and Recent Highlights” on August 09, 2018, also Seekingalpha.com with their article: “ChemoCentryx, Inc. (CCXI) CEO Dr. Thomas Schall on Q2 2018 Results – Earnings Call Transcript” published on August 10, 2018, Seekingalpha.com published: “ChemoCentryx 2018 Q2 – Results – Earnings Call Slides” on August 10, 2018. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Nasdaq.com and their article: “Recent Analysis Shows Ferroglobe, AXT, ChemoCentryx, RedHill Biopharma, GTx, and Achillion Pharmaceuticals …” published on August 20, 2018 as well as Nasdaq.com‘s news article titled: “ChemoCentryx to Present at Two Upcoming Investor Conferences” with publication date: August 22, 2018.

Since May 1, 2018, it had 0 buys, and 12 insider sales for $7.89 million activity. KANAYA SUSAN M sold $15,709 worth of stock or 1,366 shares. 10,857 shares valued at $152,028 were sold by Schall Thomas J. on Thursday, June 28.

ChemoCentryx, Inc. (NASDAQ:CCXI) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.



Source link

What is hidradenitis suppurativa



Find The Best Hidradenitis Solution Here: https://bit.ly/2AcU3eH what is hidradenitis suppurativa hidradenitis suppurativa on face hidradenitis …



Source link

How to Cure Hidradenitis Suppurativa within 7 days- Dietary Cure for Hidradenitis Suppurativa



Get Here : http://bit.ly/2Mt3EUb "Specialists Predicted I Would Never Cure My Hidradenitis Suppurativa…But Contrary To Their Prediction, I Cured My …



Source link

Pathogenetic characteristics of mesenchymal stem cells in hidradenitis suppurativa



In patients with hidradenitis suppurativa (HS) and in healthy controls, authors gauged the mesenchymal stem cells (MSC) profile. Activation of the …



Source link

Contrasting ChemoCentryx (CCXI) and Sinovac Biotech (SVA)


ChemoCentryx (NASDAQ: SVA) and Sinovac Biotech (NASDAQ:SVA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership and valuation.

Insider & Institutional Ownership

55.6% of ChemoCentryx shares are held by institutional investors. Comparatively, 16.5% of Sinovac Biotech shares are held by institutional investors. 14.5% of ChemoCentryx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk & Volatility

ChemoCentryx has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500. Comparatively, Sinovac Biotech has a beta of 0.09, suggesting that its share price is 91% less volatile than the S&P 500.

Earnings & Valuation

This table compares ChemoCentryx and Sinovac Biotech’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ChemoCentryx $82.50 million 6.69 $17.69 million $0.36 31.19
Sinovac Biotech $174.35 million 2.09 $25.80 million N/A N/A

Sinovac Biotech has higher revenue and earnings than ChemoCentryx.

Analyst Ratings

This is a summary of recent recommendations for ChemoCentryx and Sinovac Biotech, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ChemoCentryx 0 2 2 1 2.80
Sinovac Biotech 0 0 0 0 N/A

ChemoCentryx currently has a consensus target price of $17.75, indicating a potential upside of 58.06%. Given ChemoCentryx’s higher possible upside, equities research analysts clearly believe ChemoCentryx is more favorable than Sinovac Biotech.

Profitability

This table compares ChemoCentryx and Sinovac Biotech’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ChemoCentryx 18.69% 39.31% 9.53%
Sinovac Biotech N/A N/A N/A

Summary

ChemoCentryx beats Sinovac Biotech on 10 of the 12 factors compared between the two stocks.

About ChemoCentryx

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). The company is also developing Avacopan for the treatment of patients with C3 glomerulopathy (C3G), hidradenitis suppurativa (HS), and in atypical hemolytic uremic syndrome (aHUS). In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy (DN) and is being developed for patients with focal segmental glomerulosclerosis (FSGS). Further, it has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases, and in cancer. The company was founded in 1997 and is headquartered in Mountain View, California.

About Sinovac Biotech

Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People’s Republic of China. The company’s product portfolio includes vaccines against hepatitis A and B, enterovirus 71 (EV71), seasonal influenza, H5N1 and H1N1 pandemic influenza, and mumps, as well as hand, foot, and mouth diseases. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also completed phase III clinical trials for varicella and pneumococcal polysaccharide vaccines. In addition, it has completed Phase I/II clinical trials for Sabin inactivated polio; and focuses on commencing clinical trials for pneumococcal conjugate vaccine, rubella vaccine, and quadrivalent influenza vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; and Tianjin CanSino Biotechnology Inc. to develop a pneumococcal conjugate vaccine. Sinovac Biotech Ltd. was founded in 1999 and is headquartered in Beijing, the People’s Republic of China.

Receive News & Ratings for ChemoCentryx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ChemoCentryx and related companies with MarketBeat.com’s FREE daily email newsletter.



Source link

Hidradenitis Suppurativa Drug Market Cost Analysis, Revenue And Gross Margin Analysis With Its …



The Hidradenitis Suppurativa Drug Market Report covers data on global market including historical and future trends for supply, market size, prices, …



Source link

Humira Market Overview and Scope forecast 2018 to 2023 – Newszak


MarketResearchNest.com adds “Global Humira Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023” new report to its research database. The report spread across in a 121 pages with table and figures in it.

Humira (adalimumab) is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation.

Humira is used to treat many inflammatory conditions in adults, such as ulcerative colitis, Rheumatoid Arthritis, psoriatic arthritis, Ankylosing Spondylitis, plaque psoriasis, and a skin condition called hidradenitis suppurativa.

Humira is also used in adults and children to treat Crohn’s disease or juvenile idiopathic arthritis.

 Request a sample copy @:

https://www.marketresearchnest.com/report/requestsample/407359

Scope of the Report: This report focuses on the Humira in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Humira is widely used for Ankylosing Spondylitis, Rheumatoid Arthritis, Crohn’s disease and other disease. The most proportion of Humira is for Ankylosing Spondylitis, and the proportion in 2017 is about 43%, and the proportion is in decreasing trend from 2013 to 2017.

USA is the largest market, with a sales market share nearly 65% in 2017. Following USA, Europe is the second largest market with the sales market share of 30%.

The worldwide market for Humira is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017,

Market Segment by Manufacturers, this report covers

AbbVie

Eisai

Cadila Healthcare

Torrent Pharmaceuticals

Amgen

Boehringer Ingelheim

Market Segment by Regions, regional analysis covers

  • North America (United States, Canada and Mexico)
  • Europe (Germany, France, UK, Russia and Italy)
  • Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
  • South America (Brazil, Argentina, Colombia etc.)
  • Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Browse full table of contents and data tables @:

https://www.marketresearchnest.com/Global-Humira-Market-2018-by-Manufacturers-Regions-Type-and-Application-Forecast-to-2023.html

Market Segment by Type, covers

  • Humira Syringe
  • Humira Pen

Market Segment by Applications, can be divided into

  • Ankylosing Spondylitis
  • Rheumatoid Arthritis
  • Crohn’s Disease
  • Other

There are 15 Chapters to deeply display the global Humira market.

  • Chapter 1, to describe Humira Introduction, product scope, market overview, market opportunities, market risk, market driving force;
  • Chapter 2, to analyze the top manufacturers of Humira, with sales, revenue, and price of Humira, in 2016 and 2017;
  • Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
  • Chapter 4, to show the global market by regions, with sales, revenue and market share of Humira, for each region, from 2013 to 2018;
  • Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
  • Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
  • Chapter 12, Humira market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
  • Chapter 13, 14 and 15, to describe Humira sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Order a purchase Report Copy @:

https://www.marketresearchnest.com/report/purchase/407359

About Us: MarketResearchNest.com is the most comprehensive collection of market research products and services on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the Globe’s most complete and recent database of expert insights on Global industries, organizations, products, and trends.

Contact Us:-

Mr. Jeet Jain

Sales Manager

sales@marketresearchnest.com

+1-240-284-8070(U.S)

+44-20-3290-4151(U.K)

Connect with us:  Google+ | LinkedIn | Twitter | Facebook


Post Views:
13





Source link

China Accepts Its First Application for an Adalimumab Biosimilar Candidate


Bio-Thera Solutions, a Chinese-based biotechnology company, recently announced that the China National Drug Administration (CNDA) has accepted its Biologics License Application (BLA) for a potential adalimumab biosimilar, BAT1406. This is the first proposed adalimumab biosimilar to be accepted for review in China.

Click here to read more about other adalimumab biosimilars in the global pipeline.

“Bio-Thera is proud to file the first BLA for a proposed Humira biosimilar in China. We expect BAT1406 to be the first Humira biosimilar to be approved for the China market, allowing more patients to have access to an important autoimmune therapy at a more affordable cost,” said Shengfeng Li, CEO of Bio-Thera Solutions, in a statement.

The application submitted to CNDA includes a comprehensive data package that consists of analytical, preclinical, and clinical data. The clinical studies included a trial that investigated pharmacokinetic and pharmacodynamic data, as well as a phase 3 confirmatory study that investigated the safety and efficacy of the product in the treatment of ankylosing spondylitis. Bio-Thera says that it “believes these data provide confirmation that the proposed biosimilar matches the reference medicine in terms of safety, efficacy, and quality.”

BAT1406 references Humira, which is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and juvenile idiopathic arthritis. Humira, the world’s top-selling drug, earned developer AbbVie $18.4 billion in global sales in 2017.

The drug, which makes up two-thirds of AbbVie’s overall sales, is forecast to bring in nearly $21 billion by 2020, according to a Reuters report. In the United States, there are currently 2 FDA-approved adalimumab biosimilars, to be marketed as Cyltezo and Amjevita, though the products are not currently available, and Amjevita is not slated to launch until 2023.

Bio-Thera also reports that its pipeline contains biosimilar candidates of bevacizumab, which is currently being investigated in a global phase 3 clinical trial, as well as tocilizumab, ustekinumab, secukinumab, and golimumab.

 



Source link

OWC PHARMACEUTICAL RESEARCH CORP. (OTCMKTS:OWCP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers


OWC PHARMACEUTICAL RESEARCH CORP. (OTCMKTS:OWCP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As part of the Registrant’s preparation for its Phase II efficacy study (the “Psoriasis Study”) of its cannabinoid-based ointment for the treatment of skin diseases, the Registrant appointed Professor Yuval Ramot as a consultant. Professor Ramot is the Head of the Psoriasis Clinic at Hadassah – Hebrew University Medical Center in Jerusalem, Israel (“Hadassah”) and specializes in Dermatology and Venereology. Professor Ramot holds an MD and an MSc degree in Biochemistry from the Hebrew University of Jerusalem, Israel. Following his medical training, he specialized in hair research in the Department of Dermatology at Lübeck University, Germany. In March 2016, he joined the Department of Dermatology at Hadassah and the Center for Genetic Diseases of the Skin and Hair, where he focuses on research of genetic skin and hair diseases and toxicology of the skin. His main clinical interest is in inflammatory diseases of the skin. He is the director of the psoriasis and hidradenitis suppurativa clinics at Hadassah. He is the recipient of the Minerva Post-doctoral Fellowship and the Young Dermatologist International Achievement Award. He has also co-authored 10 chapters in books and more than 135 articles in peer-reviewed journals.

On August 20, 2018, Ms. Hannah Feuer, a member of the Registrant’s board of directors and Chairperson of the Registrant’s audit committee, resigned as director and Chairperson of the audit committee, effective immediately. Ms. Feuer stated she was resigning all board of directors and committee memberships on which she currently serves as a condition of acceptance related to her expected appointment to a banking corporation. Ms. Feuer’s resignation is not the result of any disagreement with the policies, practices or procedures of the Registrant. Ms. Feuer’s letter of resignation is attached hereto as Exhibit 17.1.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

OWC Pharmaceutical Research Corp. ExhibitEX-17.1 2 ex17-1.htm   August 20,…To view the full exhibit click here
About OWC PHARMACEUTICAL RESEARCH CORP. (OTCMKTS:OWCP)
OWC Pharmaceutical Research Corp. is a medical cannabis research and development company. The Company is engaged in the research and development of cannabis-based medical products (the Product Prospects) for the treatment of multiple myeloma, psoriasis and fibromyalgia, as well as development of a cannabis soluble tablet delivery system that has applications for other indications. The Company also provides consulting services to governmental and private entities to assist them with developing and implementing various medical cannabis programs. As of September 30, 2016, the Company was engaged in two business activities: work with GUMI to commercialize and market the Company’s Electromagnetic Percussion Device (the Device), and research and development of Cannabis-based medical products for the treatment of a range of medical conditions and/or diseases, such as multiple myeloma, psoriasis, post-traumatic stress disorder (PTSD) migraines and a delivery system.

An ad to help with our costs



Source link

Td Ameritrade Hldg (AMTD) Share Value Rose While Westpac Banking Trimmed Its Position; As Chemocentryx (CCXI) Valuation Rose, Shareholder Nantahala Capital Management Has Trimmed by $4.48 Million Its Stake




August 19, 2018 – By Jimmy Cauthen

TD Ameritrade Holding Corporation (NASDAQ:AMTD) Logo

Nantahala Capital Management Llc decreased its stake in Chemocentryx Inc (CCXI) by 36.46% based on its latest 2018Q1 regulatory filing with the SEC. Nantahala Capital Management Llc sold 344,586 shares as the company’s stock rose 32.26% while stock markets declined. The hedge fund held 600,488 shares of the health care company at the end of 2018Q1, valued at $8.17 million, down from 945,074 at the end of the previous reported quarter. Nantahala Capital Management Llc who had been investing in Chemocentryx Inc for a number of months, seems to be less bullish one the $555.68M market cap company. The stock increased 0.73% or $0.08 during the last trading session, reaching $11.03. About 163,923 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 83.50% since August 19, 2017 and is uptrending. It has outperformed by 70.93% the S&P500. Some Historical CCXI News: 09/03/2018 – CHEMOCENTRYX SEES 2018 CASH & INVESTMENTS USE $65M-$75M; 09/05/2018 – ChemoCentryx 1Q Loss/Shr 19c; 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS); 11/04/2018 – ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting; 09/03/2018 ChemoCentryx 4Q EPS 80c; 09/05/2018 – CHEMOCENTRYX INC – QTRLY DILUTED NET LOSS PER COMMON SHARE $0.19; 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 03/04/2018 – ChemoCentryx Presenting at Conference Apr 9

Westpac Banking Corp decreased its stake in Td Ameritrade Hldg Corp (AMTD) by 19.15% based on its latest 2018Q1 regulatory filing with the SEC. Westpac Banking Corp sold 45,140 shares as the company’s stock rose 5.82% while stock markets declined. The institutional investor held 190,555 shares of the investment bankers and brokers and service company at the end of 2018Q1, valued at $11.29B, down from 235,695 at the end of the previous reported quarter. Westpac Banking Corp who had been investing in Td Ameritrade Hldg Corp for a number of months, seems to be less bullish one the $33.72B market cap company. The stock increased 0.44% or $0.26 during the last trading session, reaching $59.41. About 1.54 million shares traded. TD Ameritrade Holding Corporation (NYSE:AMTD) has risen 57.90% since August 19, 2017 and is uptrending. It has outperformed by 45.33% the S&P500. Some Historical AMTD News: 09/04/2018 – Gabelli & Company’s 12th Annual Omaha Research Trip; 29/03/2018 – MFS Research Fund Adds TD Ameritrade, Exits Halliburton; 03/04/2018 – TD Ameritrade Institutional Welcomes Applications for 2018 NextGen Financial Planning Scholarships & Grants; 26/03/2018 – Broker TD Ameritrade suffers system-wide outage; 21/05/2018 – TD AMERITRADE UNIT ENTERED $850M SR REVOLVING LOAN FACILITY; 07/03/2018 – TD AMERITRADE HOLDING CORP AMTD.O : KBW RAISES TO OUTPERFORM FROM MARKET PERFORM; 14/03/2018 – TD Ameritrade Launches Robust Suite of Charting Tools for Retail Investors; 15/05/2018 – MILLENNIUM EXITED EQIX, AMTD, COO, PUMP, KS IN 1Q: 13F; 30/05/2018 – TD Ameritrade Announces Personalized Portfolios; 05/03/2018 – TD AMERITRADE HOLDING CORP AMTD.O : DEUTSCHE BANK RAISES TARGET PRICE TO $70 FROM $69

Analysts await TD Ameritrade Holding Corporation (NASDAQ:AMTD) to report earnings on October, 23. They expect $0.86 EPS, up 75.51% or $0.37 from last year’s $0.49 per share. AMTD’s profit will be $488.18 million for 17.27 P/E if the $0.86 EPS becomes a reality. After $0.89 actual EPS reported by TD Ameritrade Holding Corporation for the previous quarter, Wall Street now forecasts -3.37% negative EPS growth.

Among 21 analysts covering TD Ameritrade (NYSE:AMTD), 15 have Buy rating, 0 Sell and 6 Hold. Therefore 71% are positive. TD Ameritrade had 101 analyst reports since July 21, 2015 according to SRatingsIntel. Barclays Capital upgraded the stock to “Overweight” rating in Monday, January 8 report. On Friday, May 27 the stock rating was maintained by Deutsche Bank with “Buy”. On Thursday, July 13 the stock rating was maintained by Nomura with “Buy”. The stock of TD Ameritrade Holding Corporation (NASDAQ:AMTD) earned “Sell” rating by Citigroup on Wednesday, July 22. As per Thursday, July 12, the company rating was maintained by Morgan Stanley. Wells Fargo downgraded the stock to “Market Perform” rating in Monday, September 28 report. Wood maintained the stock with “” rating in Wednesday, October 7 report. Deutsche Bank maintained TD Ameritrade Holding Corporation (NASDAQ:AMTD) rating on Tuesday, March 6. Deutsche Bank has “Buy” rating and $70 target. The stock of TD Ameritrade Holding Corporation (NASDAQ:AMTD) earned “Outperform” rating by Wood on Tuesday, March 6. The stock of TD Ameritrade Holding Corporation (NASDAQ:AMTD) has “Hold” rating given on Wednesday, January 10 by Keefe Bruyette & Woods.

Since February 27, 2018, it had 0 insider purchases, and 3 selling transactions for $1.50 million activity. $299,100 worth of TD Ameritrade Holding Corporation (NASDAQ:AMTD) was sold by Quirk Steven M..

Investors sentiment decreased to 1.4 in Q1 2018. Its down 0.28, from 1.68 in 2017Q4. It fall, as 50 investors sold AMTD shares while 71 reduced holdings. 67 funds opened positions while 102 raised stakes. 505.98 million shares or 0.69% more from 502.49 million shares in 2017Q4 were reported. Jump Trading Ltd Limited Liability Company reported 3,832 shares or 0.02% of all its holdings. 11,327 were accumulated by Jefferies Grp Ltd Limited Liability Company. Bokf Na accumulated 3,590 shares. Atlantic Trust Gru Ltd Llc holds 296,740 shares. Ent Fincl Service Corp reported 0% in TD Ameritrade Holding Corporation (NASDAQ:AMTD). Natl Bank Of America Corp De owns 990,405 shares. Pitcairn has 3,663 shares. America First Limited Liability Corp accumulated 2,600 shares. First Personal Fincl reported 2,872 shares or 0.04% of all its holdings. Sg Americas Securities accumulated 7,436 shares or 0% of the stock. Da Davidson, Montana-based fund reported 6,660 shares. 10,460 are owned by Oakbrook Invests Limited Com. State Of Wisconsin Board has 0.04% invested in TD Ameritrade Holding Corporation (NASDAQ:AMTD) for 236,784 shares. Brown Brothers Harriman holds 0% of its portfolio in TD Ameritrade Holding Corporation (NASDAQ:AMTD) for 185 shares. Fdx Incorporated invested in 8,634 shares.

Westpac Banking Corp, which manages about $5007.51B US Long portfolio, upped its stake in Procter And Gamble Co (NYSE:PG) by 27,260 shares to 305,917 shares, valued at $24.25B in 2018Q1, according to the filing. It also increased its holding in Blue Apron Hldgs Inc by 997,904 shares in the quarter, for a total of 1.57 million shares, and has risen its stake in Synopsys Inc (NASDAQ:SNPS).

Investors sentiment decreased to 1 in 2018 Q1. Its down 0.30, from 1.3 in 2017Q4. It is negative, as 10 investors sold CCXI shares while 36 reduced holdings. 24 funds opened positions while 22 raised stakes. 24.22 million shares or 3.03% more from 23.51 million shares in 2017Q4 were reported. Citadel Advsr Limited Liability holds 0% or 18,829 shares in its portfolio. Public Employees Retirement Systems Of Ohio has invested 0.01% in ChemoCentryx, Inc. (NASDAQ:CCXI). Clarivest Asset Management holds 79,000 shares or 0.02% of its portfolio. 2.38 million were accumulated by Wasatch. Moreover, Proshare Advisors Ltd Liability Corporation has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 25,705 shares. Acadian Asset Management Limited Liability Company invested in 0.03% or 521,864 shares. California-based Farallon Mgmt Ltd Company has invested 0.09% in ChemoCentryx, Inc. (NASDAQ:CCXI). Pnc Finance Group reported 219,821 shares or 0% of all its holdings. Morgan Stanley reported 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Bvf Il holds 7.20M shares or 9.93% of its portfolio. Vanguard Group holds 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 1.22 million shares. Bridgeway Capital Mngmt has 50,246 shares. Jpmorgan Chase & Company accumulated 0% or 67,861 shares. The California-based Franklin Resources has invested 0.01% in ChemoCentryx, Inc. (NASDAQ:CCXI). Schwab Charles Inv Inc accumulated 0% or 43,100 shares.

Analysts await ChemoCentryx, Inc. (NASDAQ:CCXI) to report earnings on November, 6. They expect $-0.26 earnings per share, down 100.00% or $0.13 from last year’s $-0.13 per share. After $-0.14 actual earnings per share reported by ChemoCentryx, Inc. for the previous quarter, Wall Street now forecasts 85.71% negative EPS growth.

Since May 1, 2018, it had 0 buys, and 12 insider sales for $7.89 million activity. Another trade for 200,000 shares valued at $2.36 million was made by Schall Thomas J. on Tuesday, May 15. $1.34M worth of stock was sold by KANAYA SUSAN M on Tuesday, June 26.

More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Benzinga.com which released: “45 Stocks Moving In Tuesday’s Mid-Day Session” on August 14, 2018, also Nasdaq.com with their article: “ChemoCentryx Reports Second Quarter 2018 Financial Results and Recent Highlights” published on August 09, 2018, Nasdaq.com published: “ChemoCentryx to Hold Second Quarter 2018 Financial Results Conference Call on Thursday, August 9, 2018” on August 02, 2018. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Seekingalpha.com and their article: “ChemoCentryx 2018 Q2 – Results – Earnings Call Slides” published on August 10, 2018 as well as Benzinga.com‘s news article titled: “58 Biggest Movers From Yesterday” with publication date: August 15, 2018.

Among 7 analysts covering ChemoCentryx (NASDAQ:CCXI), 4 have Buy rating, 1 Sell and 2 Hold. Therefore 57% are positive. ChemoCentryx had 10 analyst reports since September 3, 2015 according to SRatingsIntel. The stock has “Neutral” rating by JP Morgan on Tuesday, August 14. The rating was maintained by JP Morgan on Tuesday, March 13 with “Overweight”. JMP Securities initiated ChemoCentryx, Inc. (NASDAQ:CCXI) on Tuesday, February 21 with “Mkt Outperform” rating. Zacks downgraded ChemoCentryx, Inc. (NASDAQ:CCXI) on Thursday, September 3 to “Sell” rating. The stock has “Buy” rating by JMP Securities on Thursday, August 10. Cowen & Co maintained the stock with “Hold” rating in Tuesday, August 8 report. The firm earned “Sell” rating on Monday, September 21 by Zacks.

TD Ameritrade Holding Corporation (NASDAQ:AMTD) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.



Source link